Prophylaxis With Apixaban in Transplant Eligible Patients With Multiple Myeloma Receiving Induction Therapy With IMiDs
Venous Thromboembolism Prophylaxis With Apixaban in Transplant Eligible Patients With Newly Diagnosed Multiple Myeloma Receiving Induction Therapy With an Immunomodulatory-based Regimen
Sponsor: Bristol-Myers Squibb
Terminated
Low recruitment
Other terminated trials from Bristol-Myers Squibb
Other Venous Thromboembolism trials with similar outcome
This PHASE2 trial investigates Venous Thromboembolism and is currently terminated or withdrawn. Bristol-Myers Squibb leads this study, which shows 6 recorded versions since 2019 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Mar 2021 — Jul 2024 [monthly]
Terminated PHASE2
Status: Suspended → Terminated
-
Jan 2021 — Mar 2021 [monthly]
Suspended PHASE2
-
Jul 2020 — Jan 2021 [monthly]
Suspended PHASE2
Status: Active Not Recruiting → Suspended
▶ Show 1 earlier version
-
Oct 2019 — Jul 2020 [monthly]
Active Not Recruiting PHASE2
First recorded
Apr 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bristol-Myers Squibb
- Instituto de Investigacion Sanitaria La Fe
For direct contact, visit the study record on ClinicalTrials.gov .